| dc.creator | Castro, Januario E | |
| dc.creator | Sandoval, José D Sandoval | |
| dc.date.accessioned | 2020-10-27T14:20:51Z | |
| dc.date.available | 2020-10-27T14:20:51Z | |
| dc.date.created | 2020-10-27T14:20:51Z | |
| dc.date.issued | 2008-07-11 | |
| dc.identifier | 2382-4603 | |
| dc.identifier | 0123-7047 | |
| dc.identifier | http://hdl.handle.net/20.500.12749/10301 | |
| dc.identifier | instname:Universidad Autónoma de Bucaramanga UNAB | |
| dc.identifier | repourl:https://repository.unab.edu.co | |
| dc.description.abstract | Resumen:Amedida que las expectativas de vida aumentan también la población de adultos mayores se incrementa, y con ello, el número de pacientes que sufren enfermedades crónicas incluyendo cáncer. Esto ha generado que en muchos paÍses industrializados la incidencia de tumores malignos y la mortalidad asociada a cáncer haya ido aumentando progresivamente, siguiendo en orden de frecuencia a las enfermedades cardiovasculares. | |
| dc.language | spa | |
| dc.publisher | Universidad Autónoma de Bucaramanga UNAB | |
| dc.relation | https://revistas.unab.edu.co/index.php/medunab/article/view/63 | |
| dc.relation | Uribe CJ, Meza EE. Incidencia de Cáncer en el área Metropolitana de Bucaramanga, 2000 - 2004. MedUNAB 2007; 10:147-72. | |
| dc.relation | American Cancer Society. Cancer Facts & Figures 2008. Atlanta, American Cancer Society, 2008. | |
| dc.relation | Pineros M, Ferlay J, Murillo R. Cancer incidence estimates at the national and distric levels in Colombia. Salud Pub Méx 2006; 48:455-65. | |
| dc.relation | Krause DS, Van Etten RA. Tyrosine kinases as targets
for cancer therapy. N Engl J Med 2005; 353:172-87. | |
| dc.relation | Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese
SF, Ford JM, et al. Activity of a specific inhibitor of the
BCR-ABL tyrosine kinase in the blast crisis of chronic
myeloid leukemia and acute lymphoblastic leukemia
with the Philadelphia chromosome. N Engl J Med 2001;
344:1038-42. | |
| dc.relation | Van Etten RA, Shannon KM. Focus on
myeloproliferative diseases and myelodysplatic
syndromes. Cancer Cell 2004; 6:547-52. | |
| dc.relation | Demetri GD, Von Mehren M, Blande CD, Van den
Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy
and safety of imatinib mesylate in advanced
gastrointestinal stromal tumors. N Engl Med 2002;
347:472-80. | |
| dc.relation | Shepherd FA, Pereira JR, Ciuleanu TE, Ciuleanu T, Tan
EH, Hirsh V, et al. Erlotinib in previously treated non-
small cell lung cancer. N Engl J Med 2005; 353:123-32. | |
| dc.relation | Slamon DJ, Leyland-Jones B, Hak S, Fuchs H, Paton V,
Bajamonde A, et al.Use of chemotherapy plus
monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med
2001;344:783-92. | |
| dc.relation | Herceptin combined with chemotherapy improves
disease-freesurvival for patients with early-stage breast
cáncer. Bethesda, Nacional Cáncer Institute, April 25,
2 0 0 5 . A c c e s s e d J u n e 1 7 , 2 0 0 5 , a t
http://www.nci.nih.gov/newscenter/pressreleases/Herc
eptinCombination2005. | |
| dc.relation | Mendelsohn J, Baselga J. The ECFG receptor family as cancer. J Clin Oncol 2005;23:6674-81.targets for cancer therapy. Oncogene 2000;19:6550-65. | |
| dc.relation | https://revistas.unab.edu.co/index.php/medunab/article/view/63/57 | |
| dc.rights | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.source | MedUNAB; Vol. 11 Núm. 2 (2008): Conjuntivitis, Salud pública, Hemato-Oncología; 73-75 | |
| dc.title | Terapia biológica en cáncer: nuevos tiempos con una visión optimista | |
